Cambridge-based Sage Therapeutics confirmed it will lay off 338 employees as the company prepares for its acquisition by Supernus Pharmaceuticals. The job cuts, scheduled to take effect on August 22, 2025, were disclosed shortly after the announcement of the $795 million acquisition deal by the Maryland-based pharmaceutical company. In state filings, Sage reported that, as of February 2025, it employed 353 full-time staff—including 122 in research and development—meaning the layoffs will affect nearly the company’s entire workforce.

Supernus Acquisition: Industry Shake-Up

The acquisition of Sage Therapeutics by Supernus is one of the year’s most significant biotech mergers and underscores the turbulent climate for mid-sized biotech firms amid tightened funding, clinical setbacks, and industry-wide consolidation. The deal, expected to close in the third quarter of 2025 pending regulatory approval and customary closing conditions, is valued at up to $795 million if certain milestones are met. According to Supernus CEO Jack Khattar, “This acquisition represents a major step in bolstering our future growth.”

The combination gives Supernus access to Sage’s prized asset—Zurzuvae (zuranolone)—the only FDA-approved oral therapy for postpartum depression. Approved in August 2023, Zurzuvae marked a milestone in women’s mental health care and remains the sole treatment of its kind available in the U.S. market. Despite its promise, Sage has struggled to achieve strong revenue growth, in part due to payer hurdles and limited insurance reimbursement, which has slowed widespread adoption even as rates of maternal mental health conditions remain high.

Sage’s Rocky Road: From Pioneering Hope to Acquisition

Founded in 2010, Sage Therapeutics was celebrated as a rising star in neuroscience drug development—especially given its early success with zuranolone. The company went public in 2014, raising nearly $90 million in its IPO. However, after the FDA declined to approve Zurzuvae for major depressive disorder (MDD) in 2023—a much broader and potentially more lucrative indication—the company was forced to retrench, slashing 40% of its workforce in August 2023 and narrowing its focus to core programs. Further, in April 2024, Sage discontinued its Parkinson’s disease clinical program after disappointing results, exacerbating its challenges.

Financial stress mounted as the biotech sector faced rising interest rates and a more cautious investor environment. In January 2025, Sage reportedly rejected a $469 million acquisition offer from Biogen, considering it undervalued the company’s long-term prospects. However, with cash reserves dwindling and the need for operational sustainability intensifying, Sage ultimately agreed to the higher-value offer from Supernus.

Layoffs and Local Impact

The scale of the layoffs—affecting almost 96% of Sage’s employees—delivers a heavy blow to Greater Boston’s workforce. The region, famed for its concentration of biotech talent and innovation, has seen a series of job reductions in 2024 and 2025 as multiple firms either downsize or get absorbed by larger players. Massachusetts, which led the U.S. in biotech VC funding for much of the past decade, is facing a marked slowdown: according to the Massachusetts Biotechnology Council (MassBio), industry employment in Boston/Cambridge declined 3% in 2024, the first such contraction in over a decade.

The layoffs at Sage follow high-profile cutbacks at other area biotechs and reflect an industry-wide adjustment to new clinical, financial, and regulatory realities. As companies refocus portfolios and chase meaningful revenue, job security for research scientists, clinicians, and other biotech professionals has become increasingly precarious.

What Supernus Gains—and the Road Ahead

For Supernus, the acquisition marks a strategic expansion into the women’s mental health segment. Supernus has a longstanding portfolio focused on central nervous system disorders, including branded and generic therapies for epilepsy, Parkinson’s disease, attention deficit/hyperactivity disorder (ADHD), and migraines. In 2024, Supernus reported annual revenues exceeding $735 million—its highest yet—bolstered by solid performances from its core epilepsy and ADHD products.

The integration of Zurzuvae offers Supernus an entry point into a largely unaddressed market. The Centers for Disease Control and Prevention (CDC) estimates that 1 in 8 women experience symptoms of postpartum depression, yet therapeutic options remain limited. “Bringing Zurzuvae to more women who need it is a priority,” Khattar stated in a post-announcement interview. Analysts expect Supernus to leverage its commercialization infrastructure to accelerate Zurzuvae’s uptake and explore new indications as payer coverage evolves.

The Bigger Picture: Biotech Consolidation Continues

Sage’s agreement with Supernus follows a broader trend of M&A activity in the biotech sector. 2024 and 2025 have seen a wave of high-profile deals as large pharma seeks pipeline diversification and innovative therapies. Recent deals include Eli Lilly’s $1.3 billion buyout of gene-editing firm Verve Therapeutics as well as increased acquisition interest from global players such as Novo Nordisk and Merck.

Analysts predict that such consolidation will likely persist as regulatory timelines extend, capital costs rise, and the demand for proven assets intensifies. While deals such as Supernus-Sage provide hope for breakthrough therapies reaching patients, they often come with painful workforce reductions and the erosion of independent biotech entrepreneurship in traditional hubs like Boston and Cambridge.

Conclusion

The announced layoffs and acquisition mark a turning point for Sage Therapeutics and signal continuing volatility in the biotech industry. As the sector recalibrates, the fates of talented professionals, innovative therapies, and regional economies hang in the balance. For Supernus, the task ahead is to capitalize on its expanded portfolio while honoring the scientific legacy and workforce of its latest acquisition.